MX337070B - Método para preparar un conjugado klh-egfrviii. - Google Patents

Método para preparar un conjugado klh-egfrviii.

Info

Publication number
MX337070B
MX337070B MX2012007283A MX2012007283A MX337070B MX 337070 B MX337070 B MX 337070B MX 2012007283 A MX2012007283 A MX 2012007283A MX 2012007283 A MX2012007283 A MX 2012007283A MX 337070 B MX337070 B MX 337070B
Authority
MX
Mexico
Prior art keywords
vaccine compositions
methods
present disclosure
compositions
composistions
Prior art date
Application number
MX2012007283A
Other languages
English (en)
Other versions
MX2012007283A (es
Inventor
Syed Saleem Ahmed
John Joseph Buckley Iii
Lavina Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Ferhana Zaman
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of MX2012007283A publication Critical patent/MX2012007283A/es
Publication of MX337070B publication Critical patent/MX337070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método preparar un conjugado KLH-EGFRvIII que comprende: a) combinar KLH con un conector de entrecruzamiento bifuncional y dejar que KLH y el conector interactúen durante un tiempo que varía de 30 x 60 minutos; b) agregar un péptido que comprende la SEQ ID NO: 1 al producto de KLH activado resultante de la etapa a) para proporcionar el conjugado KLH-EGFRvIII, en donde la relación molar conector:KLH varia de 75:1 a 325:1. Un conjugado KLH-EGFRvIII producido por el método de caracterizado porque dicho conjugado presenta una densidad de epítopes en el rango de 20-80, determinando mediante el análisis de la composición de aminoácidos.
MX2012007283A 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii. MX337070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2012007283A MX2012007283A (es) 2012-07-30
MX337070B true MX337070B (es) 2016-02-11

Family

ID=43797591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007283A MX337070B (es) 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii.

Country Status (13)

Country Link
US (3) US20130034573A1 (es)
EP (2) EP3257525A3 (es)
JP (2) JP6007105B2 (es)
KR (1) KR20120120185A (es)
CN (2) CN107412754A (es)
AU (1) AU2010334428B2 (es)
CA (1) CA2785585A1 (es)
IL (1) IL220308A0 (es)
MX (1) MX337070B (es)
NZ (2) NZ629256A (es)
RU (1) RU2581020C2 (es)
SG (2) SG10201408505SA (es)
WO (1) WO2011077309A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011217794B2 (en) * 2010-02-21 2015-01-29 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (es) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991003489A1 (en) * 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CA2206343C (en) 1994-11-28 2009-04-07 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU752227B2 (en) * 1997-07-31 2002-09-12 General Hospital Corporation, The Collagen-peptide assay method
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP2204186B1 (en) 1999-02-17 2016-04-06 CSL Limited Immunogenic complexes and methods relating thereto
HU228499B1 (en) 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
IL148672A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
SI1475101T1 (sl) * 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Farmacevtski proizvodi iz raztopine, ki vsebuje protitelo
DE60334460D1 (de) * 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
EP1639092B1 (en) * 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
NZ553244A (en) 2004-07-18 2009-10-30 Csl Ltd Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
BRPI0609932A2 (pt) * 2005-05-24 2011-10-11 Neovacs métodos para preparar um produto imunogênico anti-tnfalfa e para preparar uma composição de vacina, produto imunogênico anti-tnfalfa, composição imunogênica, e, composição de vacina
KR101399591B1 (ko) 2005-11-02 2014-06-18 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 동시 화학요법 및 면역요법
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP3936116A1 (en) * 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations

Also Published As

Publication number Publication date
RU2012131162A (ru) 2014-01-27
NZ629256A (en) 2016-02-26
NZ600978A (en) 2014-08-29
AU2010334428A1 (en) 2012-07-05
JP2013515049A (ja) 2013-05-02
IL220308A0 (en) 2012-07-31
CN102762224A (zh) 2012-10-31
US20130034573A1 (en) 2013-02-07
EP3257525A3 (en) 2018-02-28
MX2012007283A (es) 2012-07-30
EP3257525A2 (en) 2017-12-20
JP6007105B2 (ja) 2016-10-12
JP2015180667A (ja) 2015-10-15
WO2011077309A3 (en) 2011-10-06
US20150087815A1 (en) 2015-03-26
SG10201408505SA (en) 2015-02-27
EP2515934B1 (en) 2017-05-17
SG181628A1 (en) 2012-07-30
KR20120120185A (ko) 2012-11-01
RU2581020C2 (ru) 2016-04-10
AU2010334428B2 (en) 2015-05-21
WO2011077309A2 (en) 2011-06-30
CA2785585A1 (en) 2011-06-30
CN107412754A (zh) 2017-12-01
JP6146927B2 (ja) 2017-06-14
EP2515934A2 (en) 2012-10-31
US20190365886A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX336996B (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
MX2011011402A (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2011007930A (es) Conjugados de insulina cristalina.
MY152711A (en) Oral compositions containing a combination of natural extracts and related methods
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MY165955A (en) Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
WO2010111409A3 (en) Pluripotent stem cells
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
SG196784A1 (en) Stem cell cultures
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
WO2010088633A3 (en) Novel cell lines and methods
MX2011003473A (es) Composiciones para el cuidado bucal.
IN2012DN01898A (es)
IN2012DN00581A (es)
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
PH12014501369A1 (en) Oral care compositions
MY161601A (en) Films and compositions comprising the same
MX2013007230A (es) Sistemas de polimero.
IN2012DN03404A (es)
EP2435558A4 (en) PRODUCTION OF HEAVY INDUCED PLURIPOTENT STEM CELLS GENERALLY CORRECTED
MY178195A (en) Compositions, methods and uses for inducing viral growth
WO2012119103A3 (en) Compositions and methods for mobilization of stem cells
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN

Legal Events

Date Code Title Description
FG Grant or registration